The past couple of years have brought a number of advancements for the health and wellness communities. From improving technologies to more potent and effective ingredients, there’s been a lot to be thankful for. And cannabidiol (CBD), a chemical produced by the cannabis plant, definitely tops the list of new and emerging opportunities.
The sale of CBD was only just legalized by the 2018 Farm Bill, and a year after the bill was passed, the CBD industry is already worth millions, with experts estimating it will hit $20 billion by 2026. According to users, CBD is a potent medicinal compound, and although there’s barely any research to back these claims, they swear by cannabidiol’s medical abilities.
The compound is said to be effective against everything from anxiety and high blood pressure to chronic pain and insomnia, but lately, there’s been a lot of interest in the compound’s abilities as an antipsychotic. Illnesses that affect the brain have baffled scientists for years, and a lot of the medications developed to counter them aren’t as effective as we’d like them to be. And on top of that, they come with a variety of unpleasant side effects.
However, a team of researchers ran a study that could change how conditions that induce psychosis are treated. Based in King’s College, London, the researchers imaged the brains of psychosis patients under the influence of CBD and found that the hemp extract has a lot of potential as an antipsychotic.
The English researchers tested 13 patients diagnosed with psychosis using a double-blind, placebo-controlled crossover study. The patients took part in two fMRI imaging sessions, one with a placebo and one with a dose of CBD. As a control group, they used a group of healthy individuals on zero medications.
According to Sagnik Bhattacharyya, senior author of the study, the results from the study were quite illuminating. “This study provides important insight into the brain mechanisms behind the antipsychotic effects of CBD,” he says, explaining that, “It gives confidence in the antipsychotic potential of CBD by demonstrating that it targets the function of brain regions implicated in psychosis and indicating that even a single dose may ameliorate some of the brain function alterations that may underlie psychosis.”
He adds that although the results were promising, the sample size used was too small, and more research is needed before we can concretely say that CBD is an effective antipsychotic. “The finding that psychotic symptoms may show a trend towards improvement in this group even after a dose of CBD is encouraging, but requires a large scale trial to investigate if the effects would continue with long term treatment.
Experts say that these findings go a long way towards vindicating CBD industry actors, such as MCTC Holdings Inc. (OTC: MCTC), who strongly believe that cannabidiol has helpful benefits that are beyond what anyone has ever thought possible.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
